Background {#Sec1}
==========

Antipsychotic medication is the mainstay of treatment for schizophrenia \[[@CR1]\]. Agreement on the therapeutic doses of antipsychotics has been controversial; doses are determined empirically based on assessment of efficacy and tolerability for individual patients \[[@CR1]\]. When side effects emerge, management options include discontinuation of the current antipsychotic, switching to a different drug, or lowering the dose \[[@CR2]--[@CR4]\].

For example, tardive dyskinesia (TD), which occurs in up to 30% of patients receiving antipsychotics, is a serious side effect of antipsychotics for which dose reduction has been proposed \[[@CR2]--[@CR4]\]. However, controlled evidence on the effect of dose reduction for the management of TD remains limited. \[[@CR5]\]. Although novel drugs for treatment of TD are now available, management begins with consideration of antipsychotic prescribing decisions. In non-psychotic patients with TD, antipsychotic drug discontinuation may be considered and drugs may be tapered off if clinically appropriate \[[@CR6]\]. Early diagnosis and drug cessation may facilitate remission, but evidence is limited on whether or how often TD resolves, and how long it takes to do so, after discontinuation of antipsychotics \[[@CR7], [@CR8]\]. In psychotic patients, maintenance antipsychotic treatment is essential to prevent deterioration and relapse \[[@CR9]\]. Approximately 50% of patients taking antipsychotics are being treated for schizophrenia \[[@CR10]\], which has a relapse rate of 53% within 9 months after antipsychotic discontinuation \[[@CR11]\]. Antipsychotic discontinuation, which is associated with increased risk of violence, incarceration, hospitalization, increased healthcare resource utilization, and interruption of rehabilitation efforts, may be impractical in most patients with schizophrenia \[[@CR12], [@CR13]\].

Although some published evidence supports increasing doses or switching to other antipsychotics to suppress TD symptoms \[[@CR14]--[@CR16]\], these changes may raise concerns about increasing acute extrapyramidal symptoms, limiting chances of TD reversibility, and possibly destabilizing psychiatric status. Dose reduction has also been recommended in past reviews of treatment options \[[@CR5], [@CR6], [@CR17]\]. However, published meta-analyses have concluded that available data are insufficient to either support or refute treatment of TD by antipsychotic dose reduction \[[@CR5], [@CR18]\]. Furthermore, published studies of dose-reduction strategies to minimize the risk of developing extrapyramidal symptoms including TD, involving dose reductions of 50% or more, have been inconsistent but generally reported significant risks of psychotic exacerbation and relapse \[[@CR9], [@CR19]--[@CR23]\].

To further address the risks of dose reduction as a recommended treatment intervention for side effects of antipsychotic treatment, including TD, we conducted a retrospective cohort study to analyze the healthcare burden in terms of utilization of hospital-based resources resulting from ≥10% and ≥ 30% reductions in antipsychotic doses for patients with schizophrenia.

Methods {#Sec2}
=======

Study objective and data sources {#Sec3}
--------------------------------

A large retrospective cohort study using electronic medical records was conducted to compare the risk of all-cause and mental health--related inpatient admissions and emergency room (ER) visits for schizophrenia patients who were treated with a stable dose versus those who experienced a dose reduction of an oral antipsychotic monotherapy.

Medicaid data was extracted from six US states (Iowa, Kansas, Mississippi, Missouri, New Jersey, and Wisconsin). These states were chosen based on the availability of data for the analysis. Each state has its own policies regarding use and sharing of their data, and these six states had agreements in place allowing this analysis to be performed compiling and using Medicaid data from each state. All states for which data were available were included. Data representing the most recent six years from each state were analyzed, the dates of which varied by state. The overall study period ranged from 2008 to 2017 for all medical records. The Medicaid records contained complete medical claims, including diagnosis, procedures, paid amounts, pharmaceutical claims, enrollment history, and patient demographics.

Patient selection {#Sec4}
-----------------

Patients for the analysis met the following inclusion criteria: 18 years or older as of the index date; at least one diagnosis of schizophrenia in the most recent 6 years of data for each state; at least two fills of an oral antipsychotic after the first schizophrenia diagnosis; at least one antipsychotic monotherapy period that was ≥90 days with a stable dose; and a baseline period of at least 6 months of continuous enrollment prior to the index date.

Exclusion criteria included: patients receiving long-acting injectable antipsychotics; patients receiving more than one antipsychotic concurrently during the study period; and patients from New Jersey who turned 65 after 2012, as these patients were eligible for both Medicare and Medicaid, potentially preventing complete capture of drug claim information via the Medicaid database.

*"*Cases" were defined as patients with a stable-dose monotherapy period of ≥90 days who then experienced a dose reduction, defined as a reduction ≥10% from the stable dose. The date of the initial dose reduction was defined as the index date for cases. Controls were defined as patients with a stable-dose monotherapy period that lasted for ≥91 days without a dose reduction greater than 10%. The first prescription fill after the first 90-day stable-dose period was defined as the index date for controls. If a patient had multiple potential index dates that met all of the inclusion criteria, the index date used for the purposes of the study was randomly selected from the eligible potential index dates. A randomly chosen potential index date was used rather than the first such index date to avoid biasing the analysis towards earlier stages of the disease.

Cases and controls were matched 1:1 based on age, gender, state, healthcare plan type (health maintenance organization \[HMO\] vs fee-for-service \[FFS\]), index treatment (first- vs second-generation antipsychotic), and index year. All patients were followed for 2 years after the index date or until they were removed from the analysis due to either the earliest event of dose escalation (disqualification from dose-reduction analysis) or the end of eligibility (defined as any change outside of the original inclusion criteria, including medication switch, additional medication added, dose escalation, or occurrence of an outcome event). Mean duration of the follow-up period was also reported. Additional subgroup analyses were performed on the subset of cases experiencing a dose reduction of ≥30% together with matched controls.

The following patient characteristics were assessed for cases and controls during the baseline period or on the index date: characteristics (age, gender, state, and healthcare plan type); index year; index treatment; psychiatric comorbidity profile; Charlson Comorbidity Index (CCI) score, including individual comorbidities; psychotherapy; psychiatric medication; and observed disease duration, defined as the first observed schizophrenia diagnosis date prior to the index date.

Outcome measurements {#Sec5}
--------------------

Patients were assessed for all-cause inpatient admission and ER visits as well as healthcare utilization related to an inpatient admission or ER visit for either schizophrenia or another psychiatric diagnosis. Schizophrenia inpatient admissions or ER visits were identified using the International Classification of Diseases, 9th revision (ICD-9) code 295.xx and ICD-10 codes F20.x and F25.x. Psychiatric inpatient admissions or ER visits were identified by ICD-9 or ICD-10 codes for schizophrenia-spectrum and other psychotic disorders, substance-related and addictive disorders, depressive disorders, bipolar and related disorders, trauma- and stressor-induced disorders, anxiety disorders, sleep-wake disorders, and personality disorders (Additional file [1](#MOESM1){ref-type="media"}: Table S1). Patients were also assessed for TD diagnosis, corresponding to ICD-9 code 333.85 (subacute dyskinesia due to drugs) or ICD-10 code G24.01 (drug-induced subacute dyskinesia).

Statistical analysis {#Sec6}
--------------------

Descriptive statistics (mean, standard deviation, percentage) were used to describe patient demographics between case and control cohorts. Patient characteristics between cohorts were evaluated using Wilcoxon signed-rank tests for continuous variables and McNemar's tests for dichotomous variables. For comparison of study outcomes (all-cause inpatient admission or ER visit, schizophrenia-related inpatient admission or ER visit, psychiatric-related inpatient admission or ER visit), Kaplan--Meier analyses with log-rank test were used. Multivariable Cox proportional hazard models were used to compare outcomes between cases and controls, adjusting for 19 covariates, including additional patient characteristics such as age (continuous), disease duration, CCI score, psychiatric comorbidity profile, psychotherapy use, and psychiatric medication use.

Results {#Sec7}
=======

Baseline characteristics {#Sec8}
------------------------

A total of 185,267 patients were diagnosed with schizophrenia during the study period, and 19,556 case patients meeting the final inclusion criteria were matched 1:1 with control patients for the ≥10% dose-reduction analyses (Fig. [1](#Fig1){ref-type="fig"}). The resulting distribution of age, gender, state, and healthcare plan type were nearly identical between cases and controls. In both cohorts, the mean age was \~ 45.3 years and 52% were male, and \~ 44% and 18% of patients subscribed to FFS and HMO insurance plans (Table [1](#Tab1){ref-type="table"}). Differences between the cohorts include the mean observed disease duration, which was 27 months for case patients and 20 months for control patients. In addition, the mean duration of follow-up time was 4.5 months for case patients and 8.0 months for control patients (Table [1](#Tab1){ref-type="table"}). The demographics for the ≥30% dose-reduction cohorts are shown in Additional file [1](#MOESM1){ref-type="media"}: Table S2.Fig. 1Patient Selection Flow Diagram. Patients were selected for case and control cohorts from a Medicaid claims database representing six US states and the most recent 6 years of data as detailed in Methods. AP, antipsychotic; ICD, International Classification of DiseasesTable 1Baseline demographics of ≥10% dose-reduction case and control cohortsCharacteristicCase\
*N* = 19,556Control\
*N* = 19,556*P* ValueDemographics Age45.3 ± 13.845.3 ± 13.80.86 Schizophrenia duration (months)27.0 ± 17.920.1 ± 17.5\< 0.001 Male10,075 (51.5%)10,075 (51.5%)-- Duration of follow-up (months)4.5 ± 8.18.0 ± 11.7\< 0.001Insurance type FFS8562 (43.8%)8562 (43.8%)-- HMO3603 (18.4%)3603 (18.4%)-- Mixed7391 (37.8%)7391 (37.8%)--State Iowa1024 (5.2%)1024 (5.2%)-- Kansas1294 (6.6%)1294 (6.6%)-- Mississippi1761 (9.0%)1761 (9.0%)-- Missouri7765 (39.7%)7765 (39.7%)-- New Jersey5578 (28.5%)5578 (28.5%)-- Wisconsin2134 (10.9%)2134 (10.9%)--Index characteristics Index drug class  First generation2384 (12.2%)2384 (12.2%)--  Second generation17,172 (87.8%)17,172 (87.8%)-- Index year  2008480 (2.5%)480 (2.5%)--  20091388 (7.1%)1388 (7.1%)--  20101799 (9.2%)1799 (9.2%)--  20112516 (12.9%)2516 (12.9%)--  20123280 (16.8%)3280 (16.8%)--  20133378 (17.3%)3378 (17.3%)--  20142196 (11.2%)2196 (11.2%)--  20152223 (11.4%)2223 (11.4%)--  20161910 (9.8%)1910 (9.8%)--  2017376 (1.9%)376 (1.9%)Comorbidity profile Substance-related and addictive disorders4638 (23.7%)4879 (25.0%)\< 0.01 Anxiety disorders2973 (15.2%)3264 (16.7%)\< 0.001 Bipolar and related disorders4452 (22.8%)4672 (23.9%)\< 0.01 Depressive disorders4942 (25.3%)5472 (28.0%)\< 0.001 Personality disorders809 (4.1%)757 (3.9%)0.19 Schizophrenia-spectrum disorders (excluding schizophrenia)2426 (12.4%)2699 (13.8%)\< 0.001 Sleep--wake disorders1516 (7.8%)1565 (8.0%)0.36 Tardive dyskinesia37 (0.2%)51 (0.3%)0.17 Trauma- and stressor-related disorders1312 (6.7%)1446 (7.4%)\< 0.01CCI0.6 ± 1.20.6 ± 1.20.29 AIDS/HIV238 (1.2%)288 (1.5%)\< 0.05 Cancer391 (2.0%)399 (2.0%)0.80 Cerebrovascular disease765 (3.9%)717 (3.7%)0.21 Congestive heart failure759 (3.9%)722 (3.7%)0.33 Chronic pulmonary disease3901 (20.0%)3836 (19.6%)0.41 Dementia512 (2.6%)430 (2.2%)\< 0.01 Diabetes with chronic complication791 (4.0%)751 (3.8%)0.30 Diabetes without chronic complication3201 (16.4%)3066 (15.7%)0.06 Hemiplegia or paraplegia220 (1.1%)188 (1.0%)0.12 Mild liver disease800 (4.1%)834 (4.3%)0.40 Metastatic solid tumor60 (0.3%)50 (0.3%)0.39 Myocardial infarction189 (1.0%)197 (1.0%)0.72 Moderate or severe liver disease68 (0.4%)59 (0.3%)0.48 Peptic ulcer disease112 (0.6%)111 (0.6%)1.00 Peripheral vascular disease883 (4.5%)784 (4.0%)\< 0.05 Renal disease559 (2.9%)544 (2.8%)0.67 Rheumatic disease198 (1.0%)221 (1.1%)0.27Psychotherapy Psychotherapy in crisis36 (0.2%)41 (0.2%)0.65 Psychotherapy non-crisis2587 (13.2%)2791 (14.3%)\< 0.01 Psychoanalysis0 (0%)2 (0.01%)0.48Additional psychiatric medications ADHD medication523 (2.7%)513 (2.6%)0.77 Anticholinergic3998 (20.4%)3465 (17.7%)\< 0.001 Antidepressant9176 (46.9%)9214 (47.1%)0.63 Anxiety medication4961 (25.4%)4964 (25.4%)0.98 Mood stabilizer5980 (30.6%)5388 (27.6%)\< 0.001 Sedative1946 (10.0%)2112 (10.8%)\< 0.01Error represents standard deviation*ADHD* attention-deficit/hyperactivity disorder; *AIDS* acquired immunodeficiency syndrome; *CCI* Charlson Comorbidity Index; *FFS* fee-for-service; *HIV* human immunodeficiency virus; *HMO* health maintenance organization

The distribution of index drug class was also identical between the case and control cohorts (Table [1](#Tab1){ref-type="table"}). Eighty-eight percent of patients were using second-generation antipsychotics, with \~ 12% using first-generation antipsychotics. Cases had lower rates of psychiatric comorbidities and substance use disorders than controls, with the exception of personality disorders. In addition, the CCI score was also similar between cases and controls except for AIDS/HIV, dementia, and peripheral vascular disease**.** The number of TD claims reported for patients in both cohorts was extremely low, representing approximately 0.2--0.3% of the patient population.

Dosing patterns {#Sec9}
---------------

Table [2](#Tab2){ref-type="table"} shows the mean dose distribution between the case and control cohorts for the ten most commonly prescribed antipsychotic medications. Mean doses were higher in the case cohort versus the control cohort for all of the top ten medications.Table 2Dose distribution for ten most frequently used antipsychotics during stable-dose period among case and control cohortsDrugCase (N, %)Case Stable Dose (mg), Mean ± SDControl (N, %)Control Stable Dose (mg), Mean ± SDRisperidone4564 (23.3)7 ± 74135 (21.1)5 ± 6Quetiapine3871 (19.8)463 ± 2783226 (16.5)331 ± 254Olanzapine2558 (13.1)22 ± 132422 (12.4)17 ± 12Aripiprazole1838 (9.4)29 ± 472712 (13.9)22 ± 38Paliperidone1180 (6.0)70 ± 681704 (8.7)56 ± 63Haloperidol1472 (7.5)31 ± 301396 (7.1)22 ± 19Ziprasidone1185 (6.1)147 ± 611026 (5.2)125 ± 55Clozapine1251 (6.4)407 ± 180683 (3.5)405 ± 190Lurasidone467 (2.4)93 ± 42820 (4.2)68 ± 35Fluphenazine301 (1.5)20 ± 13277 (1.4)15 ± 11*SD* standard deviation

The mean and distribution of the percent reduction among cases for each of the top ten antipsychotics are shown in Table [3](#Tab3){ref-type="table"}. Patients on all ten antipsychotic medications had similar dose reductions throughout; mean dose reductions ranged from 45.3% (ziprasidone) to 57.3% (paliperidone) (Table [3](#Tab3){ref-type="table"}). For most antipsychotics, 25% of patients had a dose reduction of \~ 33% or less, and approximately half of patients had a dose reduction of 50% or less (Table [3](#Tab3){ref-type="table"}).Table 3Dose reductions for patient percentiles for the ten most frequently used antipsychotic drugsDrugNMean10th\
Percentile25th\
Percentile50th\
Percentile75th\
Percentile90th\
PercentileRisperidone456448.6%25.0%33.3%50.0%66.7%83.3%Quetiapine387148.3%25.0%33.3%50.0%66.7%80.0%Olanzapine255846.0%25.0%30.0%50.0%60.0%75.0%Aripiprazole183847.4%25.0%33.3%50.0%60.0%75.0%Paliperidone118057.3%25.0%33.3%50.0%90.0%96.3%Haloperidol147254.9%25.0%34.3%50.0%75.0%90.0%Ziprasidone118545.3%25.0%33.3%50.0%52.0%75.0%Clozapine125147.3%16.7%23.1%40.0%75.0%88.2%Lurasidone46746.9%25.0%33.3%50.0%50.0%75.0%Fluphenazine30145.7%25.0%33.3%50.0%50.0%70.0%

All-cause hospital utilization {#Sec10}
------------------------------

Patients in the case and control cohorts were evaluated for all-cause healthcare utilization by assessing the likelihood of experiencing either an inpatient admission or an ER visit. For all-cause inpatient admissions, cases with a ≥ 10% dose reduction had a first-year event rate of 34.2%, compared with a 30.9% event rate for the control group, an absolute difference of 3.3% (Fig. [2a](#Fig2){ref-type="fig"}). Dose-reduction cases were more likely to have an inpatient admission compared with controls, and this increased likelihood persisted after adjusting for differences in baseline characteristics (Table [4](#Tab4){ref-type="table"}).Fig. 2All-Cause Inpatient Admissions by Antipsychotic Dose Reduction. Patient claims were analyzed for all-cause inpatient admission for (**a**) ≥ 10% dose reductions or (**b**) ≥ 30% dose reductions of antipsychotic medication. Outcomes for case and control cohorts were assessed using Kaplan--Meier analysis and compared using a log-rank test. The number of patients at risk is represented for each time point. Case and control cohorts for ≥10%, *N* = 19,556 each; case and control cohorts for ≥30%, *N* = 15,239 eachTable 4Multivariate cox regression analysis for comparison of outcome measures between case and control cohortsOutcomeDose ReductionHR95% CI*P* ValueInpatient admission≥10%1.171.11, 1.23\< 0.001Inpatient admission≥30%1.231.17, 1.31\< 0.001ER visit≥10%1.091.05, 1.14\< 0.001ER visit≥30%1.141.08, 1.19\< 0.001Schizophrenia admission or ER visit\*≥10%1.271.19, 1.36\< 0.001Schizophrenia admission or ER visit\*≥30%1.311.21, 1.41\< 0.001Psychiatric admission or ER visit\*≥10%1.161.10, 1.23\< 0.001Psychiatric admission or ER visit\*≥30%1.211.14, 1.29\< 0.001TD claim≥10%1.390.80, 2.410.24TD claim≥30%1.600.86, 3.000.14\*See Additional file [1](#MOESM1){ref-type="media"}: Table S1 for ICD-9 and ICD-10 diagnostic codes*CI* confidence interval; *ER* emergency room; *HR* hazard ratio; *ICD* International Classification of Diseases

Cases with a ≥ 30% dose reduction showed a slightly higher rate of all-cause inpatient admission compared with the ≥10% dose-reduction cases. The difference in first-year event rate between cases and controls was 4.9% (35.4% cases vs 30.5% controls) (Fig. [2b](#Fig2){ref-type="fig"}). Dose-reduction cases again showed an increased likelihood for inpatient admission compared with controls, which remained increased after adjusting for additional patient characteristics (Table [4](#Tab4){ref-type="table"}).

For ER visits, cases with a ≥ 10% dose reduction had a first-year event rate difference of 1.4% (43.9% cases vs 42.5% controls) (Fig. [3a](#Fig3){ref-type="fig"}), whereas cases with a ≥ 30% dose reduction had a first-year event rate of difference of 3.4% (46.3% cases vs 42.9% controls) (Fig. [3b](#Fig3){ref-type="fig"}). Cases with ≥10% and ≥ 30% dose reductions were more likely to have an all-cause ER visit than controls, and this increased likelihood remained after adjusting for baseline patient characteristics (Table [4](#Tab4){ref-type="table"}).Fig. 3All-Cause Emergency Room Visits by Antipsychotic Dose Reduction. Patient claims were analyzed for all-cause emergency room visits for (**a**) ≥ 10% dose reductions or (**b**) ≥ 30% dose reductions of antipsychotic medication. Outcomes for case and control cohorts were assessed using Kaplan--Meier analysis and compared using a log-rank test. The number of patients at risk is represented for each time point. Case and control cohorts for ≥10%, *N* = 19,556 each; case and control cohorts for ≥30%, *N* = 15,239 each

Mental health--related hospital utilization {#Sec11}
-------------------------------------------

Patients in the case and control cohorts were also evaluated for mental health--related healthcare utilization by assessing the likelihood of experiencing an inpatient admission or ER visit for either a schizophrenia or psychiatric diagnosis (Additional file [1](#MOESM1){ref-type="media"}: Table S1). For schizophrenia, cases with a ≥ 10% dose reduction had a first-year event rate of 22.1%, compared with a 17.5% event rate for the control group, an absolute difference of 4.6% (Fig. [4a](#Fig4){ref-type="fig"}), and were more likely to have an inpatient admission or ER visit for schizophrenia than their control counterparts. After adjusting for differences in baseline characteristics, patients with a dose reduction of ≥10% were still more likely to have an inpatient admission or ER visit for schizophrenia than their counterparts with no dose reduction (Table [4](#Tab4){ref-type="table"})**.** Cases with a ≥ 30% dose reduction showed a slightly higher rate of schizophrenia admissions or ER visits than the ≥10% dose-reduction cases; the difference in first-year event rate between cases and controls was 5.5% (22.8% cases vs 17.3% controls) (Fig. [4b](#Fig4){ref-type="fig"}). These cases showed an increased likelihood for inpatient admission or ER visit for schizophrenia, which persisted after adjusting for additional patient characteristics (Table [4](#Tab4){ref-type="table"}).Fig. 4Inpatient Admissions or Emergency Room Visits for Schizophrenia by Antipsychotic Dose Reduction. Patient claims were analyzed for inpatient admissions or ER visits related to schizophrenia for (**a**) ≥ 10% dose reductions or (**b**) ≥ 30% dose reductions of antipsychotic medication. Outcomes for case and control cohorts were assessed using Kaplan--Meier analysis and compared using a log-rank test. The number of patients at risk is represented for each time point. Case and control cohorts for ≥10%, *N* = 19,556 each; case and control cohorts for ≥30%, *N* = 15,239 each

For psychiatric diagnoses, cases with a ≥ 10% or ≥ 30% dose reduction had a first-year event rate difference of 2.5% (27.7% cases vs 25.2% controls) and 3.8% (29.0% cases vs 25.2% controls) respectively (Fig. [5a, b](#Fig5){ref-type="fig"}). Cases with ≥10% and ≥ 30% dose reductions were more likely to have an inpatient admission or ER visit for psychiatric diagnoses than controls; when adjusted for baseline characteristics, this likelihood remained increased (Table [4](#Tab4){ref-type="table"}).Fig. 5Inpatient Admissions or Emergency Room Visits for Psychiatric-Related Diagnosis by Antipsychotic Dose Reduction. Patient claims were analyzed for inpatient admissions or ER visits related to psychiatric diagnoses for (**a**) ≥ 10% dose reductions or (**b**) ≥ 30% dose reductions of antipsychotic medication. Outcomes for case and control cohorts were assessed using Kaplan--Meier analysis and compared using a log-rank test. The number of patients at risk is represented for each time point. Case and control cohorts for ≥10%, *N* = 19,556 each; case and control cohorts for ≥30%, *N* = 15,239 each

TD claims {#Sec12}
---------

Although analysis of TD claims was limited by the small sample size of TD claims, we assessed the existing claims for the emergence of any trends. Data from all patients in both cohorts, with and without TD at baseline, were analyzed with respect to the risk of a TD diagnosis during the study period. Cases with a ≥ 10% dose reduction did not show a lower risk of having a TD claim than controls (first-year event rate of 0.21% cases vs 0.24% controls; HR: 1.39, 95% CI 0.80, 2.41, *P =* 0.24). Patients with a ≥ 30% dose reduction also showed similar results (first-year event rate of 0.23% cases vs 0.22% controls; HR: 1.60, 95% CI 0.86, 3.00, *P =* 0.14). Both comparisons represented a non-significant difference in risk of having a TD claim after adjusting for baseline characteristics (Table [4](#Tab4){ref-type="table"}).

Dose-reduction groups were also analyzed with respect to new cases of TD diagnosis during the study period compared with controls. To determine the risk of a new TD diagnosis, patients with TD at baseline were excluded (cases, *n* = 37; controls, *n* = 51). The resulting cases with a dose reduction did not have lower risk of having a TD claim compared with controls in the ≥10% group (first-year event rate of 0.16% cases vs 0.16% controls; HR: 1.66, 95% CI 0.87, 3.18, *P =* 0.12) and in the ≥30% group (first-year event rate of 0.18% cases vs 0.14% controls; HR: 1.84, 95% CI 0.89, 3.83, *P =* 0.10) after adjusting for baseline characteristics.

In addition, among patients with a TD claim during the baseline period, the percentages of patients having at least one additional TD claim during the first year of the study period were comparable between the dose-reduction cohort and the control cohort in both the ≥10% (21/37 \[57%\] vs 28/51 \[55%\], *P* = 0.33) and the ≥30% dose-reduction analyses (17/30 \[57%\] vs 21/40 \[53%\]; *P* = 0.46).

Discussion {#Sec13}
==========

Patients with antipsychotic dose reductions showed significant increases in both all-cause and mental health--related admissions and ER visits. Absolute percentage differences in first-year hospital event rates were small (1--6%), but were statistically significant given the large sample size. The clinical meaningfulness of the observed differences should be considered by healthcare decision makers, because even a 1% difference in event rates reflected an additional 196 patients using hospital services during the study period. In addition, the shorter duration of follow-up observed for cases compared with controls suggests that dose reduction not only may increase the risk of hospital utilization, but also may result in shorter periods of treatment stability.

Hospital re-admissions for schizophrenia may be an indicator of an adverse outcome or failure of antipsychotic treatment after dose reductions. The chronic nature and severity of schizophrenia contribute to its large overall healthcare burden; direct healthcare costs for schizophrenia were estimated at 38 billion US dollars in 2013 \[[@CR24]\]. Inpatient admissions represent one of the largest portions of the healthcare burden for schizophrenia, estimated in one study as 60--70% of direct costs \[[@CR25]\]. The cost for schizophrenia patients who relapse is estimated to be two to five times higher than that for non-relapsed patients \[[@CR26]\].

However, antipsychotic dose reduction in patients with schizophrenia may be necessary and appropriate for a variety of reasons; for example, patients in the dose-reduction cohort had higher mean doses to start with, as well as more cases of diabetes, which may have prompted reductions of antipsychotic doses. Although dose reduction has also been recommended to manage TD in previous practice guidelines for patients with schizophrenia who require maintenance antipsychotic treatment \[[@CR5], [@CR6]\], our results suggest that even relatively modest reductions in antipsychotic dosing, regardless of the rationale, may have significant adverse effects on outcomes for some patients. Therefore, prescribing decisions on maintenance antipsychotic treatment for preventing or treating TD should be carefully considered on an individualized basis for each patient. Apart from antipsychotic prescribing decisions, other measures, e.g., discontinuation or modification of anticholinergic drugs or treatment with vesicular monoamine transporter-2 inhibitors, may be considered in the management of TD.

The current study also attempted to evaluate antipsychotic dose reduction with respect to the diagnosis of TD and found no significant difference between stable dosing and dose reduction groups in either the number of new claims for TD during the study period based solely on the ICD-9 code of 333.85 and the ICD-10 code of G24.01 or in the persistence of a TD diagnosis following dose reduction. However, the duration of follow-up was significantly shorter in the dose-reduction group, and there were too few claims for TD in the databases compared with an expected prevalence of up to 30% in some previous studies \[[@CR27]\]. This severely limits any interpretation of the relationship between dose reduction and the treatment of TD that was present at baseline, as well as the risk of new cases of TD developing in the total patient population. We suspect that TD is vastly underreported in claims databases \[[@CR28]\], possibly due to complacency or a lack of clinical awareness, screening, approved treatments, standardization of the diagnosis or clarity regarding ICD codes. This study therefore highlights the need to document TD in a more systematic fashion. In addition, further study is needed to evaluate whether antipsychotic dose reduction is an effective treatment strategy for established cases of TD.

Strengths of the current study include the use of large patient cohorts with a 2-year follow-up period. In addition, claims data were analyzed from multiple states, with closely matched case and control groups. Study limitations include the possibility that the dose-reduction group had more hospitalizations because it represented a more-severe or chronically ill population compared with controls as suggested by the slightly longer duration of underlying schizophrenia among the case patients, the higher mean doses of antipsychotics they received, and the higher number of patients receiving clozapine at baseline. However, patients with more-severe disease would have been less likely to have doses reduced by prescribers and qualify as cases. In addition, more-severely ill patients were excluded from the analysis if they received multiple antipsychotics during the study period, had recent increases in doses (dose-reduction group), or were receiving long-acting injectable antipsychotics, all reflective of more-resistant disease. Comorbid psychiatric diagnoses that contribute to severity and hospitalizations, especially substance use, were actually more common among controls and may have biased results against our findings, resulting in worse outcomes among controls. Finally, outcome measures were controlled for numerous covariates in the Cox model that may reflect severity of illness, including psychiatric, substance use and medical co-morbidities, illness duration, and concomitant medication use. Nonadherence to treatment is another major contributor to relapse and hospitalization that may have affected differences in outcomes. However, enrollment criteria screened against including recognized nonadherent patients; patients were excluded if they received long-acting injectable antipsychotics or if they had fewer than 90 days of stable prescription monotherapy with antipsychotics prior to the index study date. Even if the dose reduction group showed greater rates of hospitalization because of nonadherence after the index date, that would still be clinically meaningful evidence suggesting untoward treatment effects of dose reduction. The high attrition during the 2 years of the study and the difference in attrition rates between cohorts were due to the cohort definitions, the differences in outcomes, and possibly nonadherence. Specifically, patients in the dose-reduction and control groups were censored at any change in antipsychotic use outside of the original inclusion criteria or after occurrence of an outcome event. The attrition and censoring of patients were accounted for in the Kaplan--Meier analyses and in the Cox models, which are statistical tools designed to handle censored or truncated time-to-event data \[[@CR29]\]. Finally, given the retrospective nature of this claims-based study, we could not confirm the reasons for antipsychotic dose reductions and whether dose reduction affected outcomes positively in relation to other clinical domains.

Conclusion {#Sec14}
==========

Results from this study show statistically significant differences in hospital utilization event rates, and suggest that dose reductions of antipsychotics may destabilize psychiatric status and lead to increased hospitalization rates in some patients with schizophrenia, resulting in damaging effects on recovery and adding to overall healthcare costs. Dose reductions had no effect on claims for TD, but this finding was confounded by the limited duration of follow-up and underreporting of the diagnosis. Therefore, decisions on dose reduction of antipsychotics in schizophrenia patients who require maintenance antipsychotic treatment, whether to prevent or reduce TD symptoms or for other reasons, should be carefully considered on an individualized basis. These results may highlight the need for alternative management strategies apart from dose reduction to reduce distressing side effects that would allow physicians to maintain effective maintenance treatment for patients with schizophrenia.
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ADHD

:   Attention-deficit/hyperactivity disorder

AIDS

:   Acquired immunodeficiency syndrome

CCI

:   Charlson Comorbidity Index

CI

:   Confidence interval

ER

:   Emergency room

FFS

:   Fee-for-service

HIV

:   Human immunodeficiency virus

HMO

:   Health maintenance organization

HR

:   Hazard ratio

ICD

:   International Classification of Diseases

TD

:   Tardive dyskinesia
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